Fortnightly review. Hereditary ovarian carcinoma

British Medical Journal

Volumn 318, Issue 7186, 1999, Pages 786-789

  Kasprzak, Lidia ^a   Foulkes, William D ^a,c   Shelling, Andrew N ^b  

^a MCGILL UNIVERSITY   (Canada)

^b NATIONAL WOMEN S HOSPITAL   (New Zealand)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

CANCER RISK; EARLY DIAGNOSIS; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; ONSET AGE; OVARIECTOMY; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; SHORT SURVEY; BASE MISPAIRING; FEASIBILITY STUDY; GENETICS; OVARY TUMOR; PEDIGREE; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

AGE OF ONSET; BASE PAIR MISMATCH; BRCA2 PROTEIN; FEASIBILITY STUDIES; FEMALE; GENES, BRCA1; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PEDIGREE; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 0033585998     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.318.7186.786     Document Type: Short Survey

References (46)

1. Foulkes WD, Narod SA. Cancers of the breast, ovary and uterus. In: Foulkes WD, Hodgson SV, eds. Inherited susceptibility to cancer. Cambridge: Cambridge University Press, 1998:205.
2. Claus EB, Schwartz PE. Familial ovarian cancer. Update and clinical applications. Cancer 1995;76:1998-2003.
3. Narod SA, Madlensky L, Bradley L, Cole D, Tonin P, Rosen B, et al. Hereditary and familial ovarian cancer in southern Ontario. Cancer 1994;74:2341-6.
4. Kerber RA, Slattery ML. The impact of family history on ovarian cancer risk. The Utah Population Database. Arch Intern Med 1995;155:905-12.
5. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents. Lyons: International Agency for Research on Cancer, 1907.
6. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457-62.
7. Aarnio M, Mecklin JP, Aaltonen LA, Nystromlahti M, Jarvinen HJ. Life-time risk of different cancers in heriditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995;64:430-3.
8. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE and the Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-5.
9. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
10. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BAJ, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nature Genet 1997;15:103-5.
11. Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, et al. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 1998;63:1341-51.
12. Serova-Sinilnikova OM, Boutrand L, Stoppa-Lyonnet D, Bressac-de-Paillerets B, Dubois V, Lasset C, et al. BRCA2 mutations in hereditary breast and ovarian cancer in France. Am J Hum Genet 1997;60:1236-9.
13. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995;56:254-64.
14. Steichen-Gersdorf E, Gallion HH, Ford D, Girodet C, Easton DF, DiCioccio RA, et al. Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet 1994;55:870-5.
15. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 1995;273:535-11.
16. Roth S, Kristo P, Auranen A, Shayehgi M, Seal S, Collins N, et al. A missense mutation in the BRCA2 gene in three siblings with ovarian cancer. Br J Cancer 1998;77:1199-202.
17. Liede A, Tonin PN, Sun CC, Serruya C, Daly MB, Narod SA, et al. Is hereditary site-specific ovarian cancer a distinct genetic condition? Am J Med Genet 1998;75:55-8.
18. Jolly KW, Malkin D, Douglass EC, Brown TF, Sinclair AE, Look AT. Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene 1994;9:97-102.
19. Prosser J, Porter D, Coles C, Condie A, Thompson AM, Chetty U, et al. Constitutional p53 mutation in a non-Li-Fraumeni cancer family. Br J Cancer 1992;65:527-8.
20. Buller RE, Skilling JS, Kaliszewski S, Niemann T, Anderson B. Absence of significant germline p53 mutations in ovarian cancer patients. Gynecol Oncol 1995;58:368-74.
21. Amos CI, Shaw GL, Tucker MA, Hartge P. Age at onset for familial epithelial ovarian cancer. JAMA 1992;268:1896-9.
22. Lynch HT, Watson P, Bewtra C, Conway TA, Hippee CR, Kaur P, et al. Hereditary ovarian cancer. Heterogeneity in age at diagnosis. Cancer 1991;67:1460-6.
23. Piver MS, Baker TR, Jishi MF, Sandecki AM, Tsukada Y, Natarajan N, et al. Familial ovarian cancer. A report of 658 families from the Gilda Radner familial Ovarian Cancer Registry 1981-1991. Cancer 1993;71:582-8.
24. Bewtra C, Watson P, Conway T, Read-Hippee C, Lynch HT. Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol 1992;11:180-7.
25. Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. Cancer 1993;71:566-72.
26. Chang J, Fryatt I, Ponder B, Fisher C, Gore ME. A matched control study of familial epithelial ovarian cancer: patient characteristics, response to chemotherapy and outcome. Ann Oncol 1995;6:80-2.
27. Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997;336:1125-30.
28. Mackey SE, Creasman WT. Ovarian cancer screening. J Clin Oncol 1995; 13:783-793.
29. Campbell S, Bhan V, Royston P, Whitehead MI, Collins WP. Transabdominal ultrasound screening for early ovarian canrer. BMJ 1989;299:1363-7.
30. Kurjak A, Zalud I. Transvaginal colour flow Doppler in the differentiation of benign and malignant ovarian masses. In: Sharp F, Mason P, Creasman W, eds. Ovarian cancer 2. London: Chapman and Hall, 1992:249-64.
31. Van Nagell JR Jr, DePriest PD, Puls LE, Donaldson ES, Gallion HH, Pavlik EJ, et al. Ovarian cancer screening in asymptomatic postmenopausal women by transvaginal sonography. Cancer 1991;68:458-62.
32. Cuckle HS, Wald NJ. The evaluation of screening tests for ovarian cancer. In: Sharp F, Mason P, Leake RE, eds. Ovarian cancer: biological and therapeutic challenges. London: Chapman and Hall, 1990:229-39.
33. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993;306:1030-4.
34. Burke W, Daly M, Garber J, Botkin J, Kahn MJE, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. JAMA 1997;277:997-1003.
35. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992;80:708-14.
36. Gross TP, Schlesselman JJ.The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 1994;83:419-24.
37. Godard B, Foulkes WD, Provencher D, Brunet JS, Tonin PN, Mes-Masson AM, et al. Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control sludy. Am J Obstet Gynecol 1998;179:403-10.
38. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998;339:424-8.
39. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-59.
40. Kerlikowske K, Brown JS, Grady DG. Should women with familal ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 1992;80:700-7.
41. Tobacman JK. Greene MH, Tucker MA, Costa J, Kase R, Fraumeni JF Jr. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982;ii:795-7.
42. NTH Consensus Development Panel on Ovarian Cancer. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. JAMA 1995;273:491-7.
43. Rubin SC, Benjamin I, Behhakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413-6.
44. Aida H, Takakuwa K, Nagata H, Tsuneki I, Takano M, Tsuji S, et al. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 1998;4:235-40.
45. Brunet JS, Narod SA, Tonin P, Foulkes WD. BRCA1 mutations and survival in women with ovarian canrer. N Engl J Med 1997;336:1256.
46. Johannson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998;16:397-404.